Albert S Baldwin

List of Publications by Citations

60 papers	17,923 citations	38 h-index	61 g-index
61 ext. papers	18,930 ext. citations	11.6 avg, IF	7.07 L-index

#	Paper	IF	Citations
60	The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annual Review of Immunology*, **1996**, 14, 649-83	34.7	5346
59	NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science*, **1998**, 281, 1680-3	33.3	2227
58	NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Molecular and Cellular Biology*, **1999**, 19, 5785-99	4.8	1130
57	Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. *Journal of Clinical Investigation*, **2001**, 107, 241-6	15.9	1029
56	Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. *Nature Medicine*, **1999**, 5, 412-7	50.5	872
55	Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. *Cell*, **1991**, 65, 1281-9	56.2	697
54	Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. *Molecular and Cellular Biology*, **2000**, 20, 1626-38	4.8	582
53	NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. *Molecular and Cellular Biology*, **1999**, 19, 5923-9	4.8	509
52	Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. *Science*, **1997**, 278, 1812-5	33.3	494
51	NF-kappaB as a therapeutic target in cancer. *Trends in Molecular Medicine*, **2002**, 8, 385-9	11.5	487
50	A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. *Nature* , **2003**, 423, 659-63	50.4	473
49	Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. *Genes and Development*, **2008**, 22, 1490-500	12.6	425
48	Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. *Oncogene*, **2000**, 19, 1123-31	9.2	380
47	Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. *Journal of Biological Chemistry*, **1997**, 272, 24113-6	5.4	308
46	Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. *Journal of Biological Chemistry*, **1998** , 273, 29411-6	5.4	302
45	Oncogenic EGFR signaling activates an mTORC2-NF-B pathway that promotes chemotherapy resistance. *Cancer Discovery*, **2011**, 1, 524-38	24.4	218
44	Regulation of cell death and autophagy by IKK and NF-B: critical mechanisms in immune function and cancer. *Immunological Reviews*, **2012**, 246, 327-45	11.3	206

43	The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. *Molecular and Cellular Biology*, **2001**, 21, 8428-36	4.8	156
42	The NF-B Pathway and Cancer Stem Cells. *Cells*, **2016**, 5,	7.9	149
41	NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. *Journal of Biological Chemistry*, **2003**, 278, 2963-8	5.4	146
40	Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. *Cancer Research*, **2010**, 70, 3537-46	10.1	139
39	IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. *Journal of Biological Chemistry*, **2006**, 281, 26976-84	5.4	120
38	Expression of the Bcl-3 proto-oncogene suppresses p53 activation. *Genes and Development*, **2006**, 20, 225-35	12.6	112
37	The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. *Oncogene*, **1998**, 16, 1869-77	9.2	86
36	Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IB kinase (IKK). *Journal of Biological Chemistry*, **2014**, 289, 25227-40	5.4	81
35	Deletion of the NF-B subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. *Blood*, **2013**, 121, 5015-24	2.2	80
34	Apoptosis promotes a caspase-induced amino-terminal truncation of IkappaBalpha that functions as a stable inhibitor of NF-kappaB. *Journal of Biological Chemistry*, **1999**, 274, 20664-70	5.4	76
33	IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. *PLoS ONE*, **2010**, 5, e9428	3.7	75
32	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. *Science*, **2018**, 361, 290-295	33.3	73
31	GSK-3promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-B. *Cancer Discovery*, **2013**, 3, 690-703	24.4	70
30	Chemotherapy-induced muscle wasting: association with NF-B and cancer cachexia. *European Journal of Translational Myology*, **2018**, 28, 7590	2.1	68
29	Oncogenic PI3K mutations lead to NF-B-dependent cytokine expression following growth factor deprivation. *Cancer Research*, **2012**, 72, 3260-9	10.1	65
28	Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. *Cancer Research*, **2007**, 67, 6263-9	10.1	60
27	Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. *Journal of Immunology*, **2008**, 180, 7582-9	5.3	59
26	p85SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. *Molecular Cell*, **2012**, 45, 719-30	17.6	55

25	IKK/nuclear factor-kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment. *Advances in Cancer Research*, **2014**, 121, 125-145	5.9	47
24	NEMO-binding domain peptide inhibits constitutive NF-Β activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. *Clinical Cancer Research*, **2011**, 17, 4661-71	12.9	43
23	A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. *PLoS ONE*, **2014**, 9, e95404	3.7	38
22	PI3K/Akt promotes feedforward mTORC2 activation through IKK *Oncotarget*, **2016**, 7, 21064-75	3.3	34
21	TBK1 Is a Synthetic Lethal Target in Cancer with Loss. *Cancer Discovery*, **2020**, 10, 460-475	24.4	33
20	Roles for the IKK-Related Kinases TBK1 and IKK n Cancer. *Cells*, **2018**, 7,	7.9	33
19	Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. *PLoS ONE*, **2009**, 4, e6992	3.7	31
18	IKK/NF-Β signaling contributes to glioblastoma stem cell maintenance. *Oncotarget*, **2016**, 7, 69173-69187	3.3	31
17	Development of a high-throughput assay for identifying inhibitors of TBK1 and IKK *PLoS ONE*, **2012**, 7, e41494	3.7	29
16	IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity. *Genes and Cancer*, **2014**, 5, 41-55	2.9	28
15	Noncanonical NF-Β in Cancer. *Biomedicines*, **2018**, 6,	4.8	27
14	Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G arrest independent of DRD2. *Journal of Biological Chemistry*, **2018**, 293, 15977-15990	5.4	27
13	IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. *Molecular Cancer Therapeutics*, **2008**, 7, 391-7	6.1	22
12	Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer. *PLoS ONE*, **2016**, 11, e0165005	3.7	21
11	Cytosolic DNA Promotes Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation by TANK-binding Kinase 1 (TBK1) to Restrain STAT3 Activity. *Journal of Biological Chemistry*, **2017**, 292, 5405-5417	5.4	19
10	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. *Molecular Cell*, **2020**, 77, 1294-1306.e5	17.6	19
9	TBK1 Limits mTORC1 by Promoting Phosphorylation of Raptor Ser877. *Scientific Reports*, **2019**, 9, 13470	4.9	15
8	IKK promotes cytokine-induced and cancer-associated AMPK activity and attenuates phenformin-induced cell death in LKB1-deficient cells. *Science Signaling*, **2018**, 11,	8.8	15

List of Publications

7	Loss of IKK but Not NF-B p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term Hematopoietic Stem Cells. *PLoS ONE*, **2015**, 10, e0130441	3.7	14
6	Expanding the View of IKK: New Substrates and New Biology. *Trends in Cell Biology*, **2021**, 31, 166-178	18.3	13
5	Signal transducer and activator of transcription 3 () regulates host defense and protects mice against herpes simplex virus-1 (HSV-1) infection. *Journal of Leukocyte Biology*, **2017**, 101, 1053-1064	6.5	9
4	USP37 promotes deubiquitination of HIF2 in kidney cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 13023-13032	11.5	9
3	Selective Effects of Thioridazine on Self-Renewal of Basal-Like Breast Cancer Cells. *Scientific Reports*, **2019**, 9, 18695	4.9	7
2	Genome-wide DNA methylation analysis of KRAS mutant cell lines. *Scientific Reports*, **2020**, 10, 10149	4.9	2
1	Using RNA interference in lung cancer cells to target the IKK-NF-B pathway. *Methods in Molecular Biology*, **2015**, 1280, 447-58	1.4	1